Non-Current Liabilities
Operating Lease Liabilities
Alnylam Pharmaceuticals Operating Lease Liabilities decreased by 3.1% to $218.03M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.2%, from $230.06M to $218.03M. Over 5 years (FY 2020 to FY 2025), Operating Lease Liabilities shows a downward trend with a -5.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ3 2019
Last reportedQ4 2025
How to read this metric
An increase reflects long-term expansion of the leased asset base, while a decrease indicates a reduction in long-term lease commitments.
Detailed definition
This represents the portion of operating lease obligations that are due beyond the next twelve months. It reflects the l...
Peer comparison
Standard long-term liability for companies with significant real estate or equipment footprints.
Metric ID:
operating_lease_liabilities_non_currentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $288.56M | $286.03M | $281.35M | $277.39M | $272.02M | $266.32M | $261.34M | $259.40M | $253.42M | $247.71M | $243.10M | $237.83M | $239.35M | $236.03M | $229.54M | $230.06M | $224.45M | $223.42M | $225.09M | $218.03M |
| QoQ Change | — | -0.9% | -1.6% | -1.4% | -1.9% | -2.1% | -1.9% | -0.7% | -2.3% | -2.3% | -1.9% | -2.2% | +0.6% | -1.4% | -2.7% | +0.2% | -2.4% | -0.5% | +0.7% | -3.1% |
| YoY Change | — | — | — | — | -5.7% | -6.9% | -7.1% | -6.5% | -6.8% | -7.0% | -7.0% | -8.3% | -5.5% | -4.7% | -5.6% | -3.3% | -6.2% | -5.3% | -1.9% | -5.2% |
Range$218.03M – $288.56M
CAGR-5.7%
Avg YoY Growth-5.8%
Median YoY Growth-6.0%
Operating Lease Liabilities at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's operating lease liabilities?
- Alnylam Pharmaceuticals (ALNY) reported operating lease liabilities of $218.03M in Q1 2026.
- How has Alnylam Pharmaceuticals's operating lease liabilities changed year-over-year?
- Alnylam Pharmaceuticals's operating lease liabilities decreased by 5.2% year-over-year, from $230.06M to $218.03M.
- What is the long-term trend for Alnylam Pharmaceuticals's operating lease liabilities?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's operating lease liabilities has grown at a -5.1% compound annual growth rate (CAGR), from $293.04M to $225.09M.
- What does operating lease liabilities mean?
- The amount of lease payments due after one year.